JPLA
TNXP icon

Joseph P. Lucia & Associates’s Tonix Pharmaceuticals TNXP Stock Holding History

Joseph P. Lucia & Associates’s Portfolio TNXP Stock Details TNXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-200
Closed -$6.6K – 152
2024
Q4 		$6.6K Buy
+200
New +$4.16K ﹤0.01% 146

Other funds holding TNXP

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
CIAM
Caitong International Asset Management Hong Kong $541M AUM 1,009.51% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
CIBC Asset Management
CIBC Asset Management Toronto, Ontario, Canada $40.9B AUM 35.96% 1-Year Est. Return

Joseph P. Lucia & Associates's TNXP Position: Q1 2025 in Review

Joseph P. Lucia & Associates sold out of Tonix Pharmaceuticals (TNXP) in Q1 2025, closing a stake of 200 shares — an estimated $6.6K sold.

Joseph P. Lucia & Associates first reported a position in TNXP in Q4 2024 and held it in 1 quarter. The position peaked at $6.6K in Q4 2024. 26 funds tracked by Wall St. Rank hold TNXP as of Q1 2025.

  • Joseph P. Lucia & Associates reported no remaining Tonix Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Joseph P. Lucia & Associates sold 200 Tonix Pharmaceuticals shares in Q1 2025, an estimated $6.6K.
  • Joseph P. Lucia & Associates first reported a position in Tonix Pharmaceuticals in Q4 2024 and held it in 1 quarter.
  • Joseph P. Lucia & Associates's Tonix Pharmaceuticals position peaked at $6.6K in Q4 2024.
  • 26 funds tracked by Wall St. Rank held Tonix Pharmaceuticals as of Q1 2025.

Based on Joseph P. Lucia & Associates's 13F filing for Q1 2025, filed 14 May 2025.